Status:
COMPLETED
Immunoblot, Chemiluminescence and ImmunoCap Allergen Specific IgE Evaluation of in Allergic Rhinitis Patients
Lead Sponsor:
Zagazig University
Conditions:
Diagnoses Disease
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
In the present study the investigators assay house dust mites (HDMs) IgE in sera of allergic rhinitis patients (AR) using immunoblotting, chemiluminescence, and ImmunoCAP assays to compare between the...
Detailed Description
All allergic rhinitits patients who were monosensitized to mixed HDMs, identified by SPT, will be subjected to complete history taking and assessment of the inclusion and exclusion criteria, performan...
Eligibility Criteria
Inclusion
- Patient consent.
- Patient with (18-40) years age known to be allergic rhinitis.
- Patient with IgE mediated allergic rhinitis (positive total IgE).
- Patient with positive skin prick testing and monosensitized to HDM
Exclusion
- Patient refusal
- Patients taking oral corticosteroid.
- Patients taking anti-IgE injections.
- Patients taking intranasal corticosteroid.
- Patient with non- IgE mediated allergic rhinitis.
- Patients with chronic diseases.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06137495
Start Date
December 1 2020
End Date
June 30 2023
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University Faculty of Medicine
Zagazig, Sharqia Province, Egypt, 44519